Summary
5.48
0.16
(2.91%)
07/21/2026
Vanda Pharmaceuticals Inc. (VNDA)Key Facts
Performance
Historical returns1D
2.91%
1W
-9.06%
1M
n/a
3M
-23.89%
6M
-31.00%
1Y
14.16%
5Y
-71.93%
Snapshot
Key statisticsClose
5.48
Change
0.16
Change %
2.91%
Open
5.30
Day Range
5.28 – 5.51
Volume
532,329
Avg Vol (20d)
858,742
Rel Vol
0.62x
52W Range
4.14 - 9.94
vs 52W High
-44.92%
vs 52W Low
32.25%
Gap
-0.06
Market Cap
USD 262.08M
Beta
0.71
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 0× | -6.41% |
| 1-Month | 6× | -16.79% |
| 3-Month | 5× | -27.58% |
| 6-Month | 8× | -42.73% |
| YTD | 4× | -42.73% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 19× | -42.73% |
| 2-Year | 9× | -42.73% |
| 3-Year | 11× | -42.73% |
| 5-Year | 3× | -74.10% |
| 10-Year | 39× | -82.60% |
Financial SnapshotFY 2025
Full financialsRevenue
USD 216.11M
+8.7% YoY
Net Income
-USD 220.47M
+1,066.5% YoY
EPS
-3.74
+1,068.8% YoY
Gross Margin
94.0%
Operating Margin
-70.0%
Net Margin
-102.0%
EBITDA
-USD 139.25M
Free Cash Flow
-USD 110.44M
-51.1% margin
ROE
-67.4%
ROA
-45.1%
Debt / Equity
0.04x
net debt -USD 72.23M
Cash & Equiv.
USD 84.85M
Fundamental Ratings
MainC+
RecommendedSell
DCFStrong Sell
ROEStrong Sell
ROAStrong Sell
Debt/EquityBuy
P/EStrong Sell
P/BBuy
Latest Earnings
- VNDA reported last earnings on 2026-05-06.
- EPS of $-0.82 vs $-0.53 estimated — surprise $-0.29.
- Revenue of $52M vs $55M estimated — surprise $-3M.
News
All newsVanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
WASHINGTON, July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's...
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
WASHINGTON, July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series...
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston, Massachusetts on Thursday, July 16, 2026.
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
WASHINGTON, July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational antisense oligonucleotide therapy for the treatment of...
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
WASHINGTON, May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab, a high‑affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the...
Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss
Vanda Pharmaceuticals is rated a buy, supported by new drug approvals, a diversified clinical pipeline, and strong top-line growth potential. VNDA's near-zero debt and undervalued price/book ratio offer balance sheet strength and significant upside, with Wall St. forecasting considerable price...
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
WASHINGTON, May 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in May 2026: The Bank of America Securities Global Health Care Conference 2026 in Las Vegas, Nevada on Tuesday,...
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
Fanapt ® net product sales rose 26% to $29.6 million; total prescriptions increased 32% and new-to-brand prescriptions surged 76% NEREUS™ (tradipitant) launched via nereus.us, an innovative direct-to-consumer platform – the first new prescription medicine in more than 40 years for the...
Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know
The mean of analysts' price targets for Vanda (VNDA) points to a 105% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Consumers can now order NEREUS™ directly at nereus.us WASHINGTON, May 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States for the prevention of vomiting induced by motion in...
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
Conference Call and Webcast to Follow WASHINGTON, April 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2026 on Wednesday, May 6, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET...
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in New England Journal of Medicine (NEJM) Evidence1. The...
Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
Incyte (INCY) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.16 per share a year ago.
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
WASHINGTON, April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22, 2026.
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Passes Above 200-Day Moving Average – Time to Sell?
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report)'s share price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $6.67 and traded as high as $7.29. Vanda Pharmaceuticals shares last traded at $6.99, with a volume of 1,200,996...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Increase in Short Interest
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 5,310,265 shares, a growth of 65.9% from the March 15th total of 3,200,424 shares. Based on an average...
Contrasting Vanda Pharmaceuticals (NASDAQ:VNDA) and Atrinsic (NASDAQ:PTIX)
Vanda Pharmaceuticals (NASDAQ: VNDA - Get Free Report) and Atrinsic (NASDAQ: PTIX - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst...